Investing.com - 德意志银行首次覆盖Atai Life Sciences ...

- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to initiate a Phase 2 study in treatment-resistant ...

atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living with mental health conditions Continued operational ...

NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop ...

VLS-01, a proprietary oral transmucosal film (OTF) formulation of DMT, was well-tolerated with a favorable safety profile Pharmacokinetic and pharmacodynamic data confirmed systemic delivery of DMT ...

Atai Life Sciences (NASDAQ: ATAI), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer ...

AtaiBeckley Inc. (OTCQX: ATAI)首席医疗官Craig Kevin James于2026年3月20日出售了10万股普通股。此次出售的执行价格为3.55美元,总计35.5万美元。该股票目前交易价格为3.37美元,尽管过去一年实现了115%的惊人回报,但过去一周下跌了7.4%。根据InvestingPro的数据,该平台为ATAI提供了12条额外的独家提示,该股票表现出相当大的 ...

The biotech published a readout from a clinical study of an antidepressant drug. It is developing the medication in collaboration with a privately held peer. That drug, tagged BPL-003 by Atai, is an ...

View AtaiBeckley Inc. ATAI stock quote prices, financial information, real-time forecasts, and company news from CNN.

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 ...